Globally, approximately 58 million people are chronically infected with HCV, resulting in 290,000 annual deaths due to complications such as liver cirrhosis and liver cancer.
SEQUANA MEDICAL ANNOUNCES DECISION OF MAJOR SHAREHOLDERS TO INVEST IN SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN Ghent, Belgium, 6 December 2024 – (Euronext Brussels: SEQUA) (the "Company" or "Sequana ...
Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s ...
In 2021, alcohol-related liver cirrhosis accounted for about a quarter of the 46·4 million disability-adjusted life-years (DALYs) lost from liver disease globally, making alcohol a leading cause of ...